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Proinflammatory responses induced by Toll-like receptors (TLRs)
are dependent on the activation of the NF-ĸB and mitogen-
activated protein kinase (MAPK) pathways, which coordinate the
transcription and synthesis of proinflammatory cytokines. We
demonstrate that BCL-3, a nuclear IĸB protein that regulates NF-ĸB,
also controls TLR-induced MAPK activity by regulating the stabil-
ity of the TPL-2 kinase. TPL-2 is essential for MAPK activation by
TLR ligands, and the rapid proteasomal degradation of active TPL-2
is a critical mechanism limiting TLR-induced MAPK activity. We re-
veal that TPL-2 is a nucleocytoplasmic shuttling protein and identify
the nucleus as the primary site for TPL-2 degradation. BCL-3
interacts with TPL-2 and promotes its degradation by promoting
its nuclear localization. As a consequence, Bcl3−/− macrophages
have increased TPL-2 stability following TLR stimulation, leading
to increased MAPK activity and MAPK-dependent responses.
Moreover, BCL-3–mediated regulation of TPL-2 stability sets the
MAPK activation threshold and determines the amount of TLR
ligand required to initiate the production of inflammatory cyto-
kines. Thus, the nucleus is a key site in the regulation of TLR-
induced MAPK activity. BCL-3 links control of the MAPK and NF-ĸB
pathways in the nucleus, and BCL-3–mediated TPL-2 regulation im-
pacts on the cellular decision to initiate proinflammatory cytokine
production in response to TLR activation.
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Toll-like receptor (TLR) activation is essential for effectiveinflammatory responses to infection or injury. TLR-induced
responses are primarily dependent on the activation of the NF-
ĸB and mitogen-activated protein kinase (MAPK) pathways (1,
2). Activation of NF-ĸB leads to the transcription of a large
number of proinflammatory cytokines, chemokines, and adhesion
molecules (3). TLR-induced activation of the MAPK pathway
controls the expression of transcription factors such as Fos, Egr1,
and Elk1 as well as certain cytokines and immunomodulators (2,
4–6). MAPK activation also plays a critical role in the post-
transcriptional control of cytokine expression through the regu-
lation of messenger RNA (mRNA) stability, transport, and
translation (2). Indeed, NF-ĸB activation in the absence of MAPK
activation does not lead to inflammation because increased tran-
scription of cytokine-encoding genes, such as Tnf, is not accom-
panied by mRNA translation (7). Thus, the coordinated control of
the NF-ĸB and MAPK pathways is required to ensure that in-
flammatory responses are appropriately initiated.
Although TLR activation of the NF-ĸB and MAPK pathways
both require the IKKβ kinase (8), each pathway possesses dis-
tinct features that determine the consequences of TLR ligation.
IKKβ-triggered degradation of IĸBα induces the activation of
NF-ĸB proportionally to the level of stimulus, thereby leading to
a graded transcriptional response (9, 10). In contrast, the MAPK
pathway is ultrasensitive; that is, activation in response to in-
creasing concentrations of a stimulus is nonlinear and occurs
mostly over a narrow range of ligand concentrations (11, 12).
This effectively enables the MAPK pathway to remain insensitive
to low levels of stimulus while responding robustly to higher
levels (13). Importantly, at TLR ligand concentrations below the
MAPK activation threshold, NF-ĸB activation occurs but does
not lead to the production of proinflammatory mediators, al-
though, in macrophages at least, it can prime cells for subsequent
responses (7, 13).
The serine/threonine kinase TPL-2 (MAP3K8) is essential for
MAPK activation by TLR ligands and by cytokines including
TNFα and IL1β (14–16). In resting cells, TPL-2 is bound by NF-ĸB
p105 which prevents it from interacting with, and phosphory-
lating, MEK1 (14, 16). Activation of IKKβ phosphorylates TPL-
2–bound p105, triggering its ubiquitination and proteasomal
degradation. This liberates active TPL-2, which in turn initiates
the MAPK cascade by phosphorylating and activating MEK1
(17, 18). Active TPL-2 is highly unstable and is rapidly degraded
by the proteasome (14, 16). This is the primary mechanism limiting
TLR-induced MAPK activation. Indeed, in the absence of p105
(Nfkb1), proteasomal degradation leads to extremely low levels of
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TPL-2 protein, and Nfkb1−/− macrophages and mice are deficient
in TLR-induced MAPK activation (16, 17).
Here we show that the IκB protein BCL-3, a known negative
regulator of NF-κB transcriptional activity (19), is also an im-
portant negative regulator of TLR-induced MAPK activity. We
establish TPL-2 as a nucleocytoplasmic shuttling protein and
identify an N-terminal nuclear export sequence (NES) in TPL-2
that is sufficient to mediate nuclear export. We demonstrate that
TPL-2 undergoes ubiquitination and proteasomal degradation in
the nucleus and that nuclear localization is a critical determinant
of TPL-2 half-life. BCL-3 binds TPL-2 to promote its protea-
somal degradation in the nucleus and thereby regulates MAPK
activity. Importantly, BCL-3–mediated inhibition of TPL-2 determines
the TLR ligand threshold required to induce proinflammatory
cytokine production, and unchallenged Bcl3−/−mice have elevated
levels of circulating proinflammatory cytokines. Together, these
findings identify BCL-3 as a unique factor linking the regulation of
the MAPK and NF-ĸB pathways in the nucleus that plays a critical
role in the cellular decision to initiate production of inflammatory
cytokines.
Results
BCL-3 Negatively Regulates MAPK-Dependent Gene Expression. We
previously identified the IĸB protein BCL-3 as a negative regu-
lator of TLR-induced transcriptional responses through the sta-
bilization of NF-κB p50 homodimer repressor complexes (19, 20).
On further analysis we observed that, in addition to inhibiting the
expression of NF-κB–regulated proinflammatory genes, BCL-3
also limits the TLR-inducible transcription of a number of im-
mediate/early genes that have previously been shown to rely on
MAPK activity for expression (21). Bone marrow-derived mac-
rophages (BMDMs) from wild-type (WT) and Bcl3−/− mice were
left untreated or stimulated with lipopolysaccharides (LPS) (10 ng/mL)
and then analyzed by probe-directed RNA-sequencing (RNA-
seq) to measure the core TLR-induced transcriptional response.
As expected (19), Bcl3−/− BMDMs were hyper-responsive to LPS
stimulation as measured by the elevated expression of NF-κB
target genes including Tnf, Il6, and Il1b (Fig. 1A). However, LPS-
treated Bcl3−/− BMDMs also showed significantly increased levels
of mRNA for the MAPK-dependent genes Fos, Egr1, Egr2, and
Nr4a1 when compared to LPS-treated WT controls (Fig. 1A and
SI Appendix, Table S1). These data were confirmed by qPCR
analysis in independent experiments that also demonstrated in-
creased expression of the MAPK-dependent gene Dusp5 (Fig.
1B). Stimulation of BMDMs with other TLR ligands (CpG,
PAM3CSK4, or Poly[I:C]) or TNFα also led to increased expres-
sion of MAPK target genes in Bcl3−/− cells compared to WT cells
(SI Appendix, Fig. S1).
To confirm the role of MAPK activity (21) in the enhanced
expression of these genes, WT and Bcl3−/− BMDMs were stim-
ulated with LPS (10 ng/mL) in the presence of increasing con-
centrations of the MEK1 inhibitor U0126 and the expression of
Egr1 measured by qPCR. The LPS-inducible expression of Egr1
was highly MAPK-dependent in both WT and Bcl3−/− cells, which
Fig. 1. Increased MAPK-dependent gene expression in Bcl3−/− BMDMs. (A) Heat map of RNA-seq data from WT and Bcl3−/− BMDMs stimulated with LPS
(10 ng/mL) for the indicated times. Selected genes are indicated. (B) qPCR analysis of the expression of selected genes in WT and Bcl3−/− BMDMs stimulated
with LPS (10 ng/mL) for the indicated times. (C) qPCR analysis of Egr1 expression (10 ng/mL for 60 min) in WT and Bcl3−/− BMDMs pretreated for 30 min with
increasing amounts (0 to 0.5 μM) of the MEK1 inhibitor U1026 (MEKi). Relative levels of Egr1 mRNA are expressed as a percentage (%) of the maximum for
each genotype. (D) qPCR analysis of LPS-induced expression (10 ng/mL for 60 min) of selected genes in WT and Bcl3−/− BMDMs pretreated or untreated with
MEKi (0.5 μM). Data in B–D are presented as the mean ± SEM and are representative of 3 independent experiments. Data were analyzed by 2-way ANOVA
with the Sidak multiple comparisons test (B and C) or unpaired Student’s t test (D). ns, not significant; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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were equally sensitive to MEK1 inhibition (Fig. 1 C and D).
Similar results were seen for LPS-induced expression of Dusp5,
Fos, and Egr2 while the expression of NF-ĸB–dependent Tnf was
insensitive to MEK1 inhibition in both WT and Bcl3−/− cells (Fig.
1D). Together, these data identify a role for BCL-3 in limiting the
MAPK-dependent expression of immediate/early genes following
TLR stimulation and suggest an NF-κB–independent role for
BCL-3 in regulating TLR responses.
BCL-3 Inhibits TPL-2 Activation of the MAPK Pathway. We next an-
alyzed the activation of the MAPK pathway in WT and Bcl3−/−
BMDMs stimulated with LPS (10 ng/mL) using phospho-specific
antibodies against MEK1 and ERK1/2. This revealed a signifi-
cant increase in the LPS-induced activation of the MAPK
cascade in Bcl3−/− cells compared to WT cells, which was char-
acterized by increased phosphorylation of MEK1 and ERK1/2
(Fig. 2 A–D). LPS-induced activation of the p38 and JNK path-
ways, as measured by phosphorylation of p38 and c-Jun, was not
significantly different between WT and Bcl3−/− cells (SI Appen-
dix, Fig. S2). The increased LPS-induced activation of ERK1/2 in
Bcl3−/− cells was sensitive to treatment with MEK1 inhibitor,
demonstrating that it results from enhanced MEK1 activity (Fig.
2E). TPL-2 (MAP3K8) is the apical kinase of the MAPK path-
way activated by TLRs and TNFR, and it directly phosphory-
lates and activates MEK1. To investigate the effect of BCL-3 on
TPL-2–induced MAPK activity independently of TLR activa-
tion, we measured the impact of BCL-3 expression on TPL-2–
induced AP-1 reporter activity using RAW 264.7 macrophages.
Coexpression of BCL-3 and TPL-2 blocked TPL-2–induced AP-
1 reporter activity, demonstrating that BCL-3 inhibits TPL-2–
induced MAPK activity (Fig. 2F). Overexpression of NF-ĸB
p50 mimics the effect of BCL-3–mediated inhibition of NF-ĸB
target gene expression (19, 20, 22), but this did not block TPL-2–
induced AP-1 reporter activity (Fig. 2F). Together, these data
indicate that BCL-3 can inhibit MAPK activation by TPL-
2 through an NF-ĸB–independent pathway.
BCL-3 Interacts with TPL-2 and Promotes Its Localization to the
Nucleus. TLR-induced activation of the MAPK and NF-ĸB
pathways is linked via NF-ĸB p105, which acts as an inhibitor
of both pathways (23). p105 inhibits MAPK activation by binding
to TPL-2 through its C-terminal ankyrin repeat domain (16).
This domain bears significant structural and sequence homology
with the central ankyrin repeat domain of BCL-3, suggesting a
potential physical interaction between BCL-3 and TPL-2. TPL-2
protein is expressed as 2 isoforms (58 and 52 kDa) due to al-
ternative translation initiation sites of both endogenous and
overexpressed protein (24). Coimmunoprecipitation experiments
using HEK293T cells transiently transfected with plasmids
encoding BCL-3 and TPL-2 revealed that BCL-3 and TPL-2 can
interact in cells (Fig. 3A), while coimmunoprecipitation experi-
ments using THP-1 monocytes demonstrated the interaction of
endogenous BCL-3 and TPL-2 (Fig. 3B). NF-ĸB p105 and
p50 are not required for the interaction of BCL-3 and TPL-2
since BCL-3 and TPL-2 also coimmunoprecipitated when
expressed in Nfkb1−/− mouse embryonic fibroblasts (MEFs) (Fig.
3C). Additional experiments using a kinase-inactive mutant of
TPL-2 (D270A) revealed that TPL-2 kinase activity is needed for
interaction with BCL-3, a requirement similar to that reported
for the interaction of TPL-2 with p105 (24) (Fig. 3D). These data
raise the possibility that the interaction of BCL-3 with TPL-2
inhibits TPL-2 kinase activity to limit the activation of the
Fig. 2. BCL-3 inhibits MAPK activity. WT and Bcl3−/− BMDMs were stimulated with LPS (10 ng/mL) for the indicated times, and phosphorylation of MEK1 (A)
and ERK1/2 (B) were analyzed by immunoblot. Phosphorylation of MEK1 (C) and ERK1/2 (D) were quantified relative to total kinase and β-actin loading
controls for 3 independent experiments. (E) WT and Bcl3−/− BMDMs were untreated or pretreated for 30 min with the MEK1 inhibitor U0126 (0 to 0.5 μM)
prior to stimulation with LPS (10 ng/mL for 5 min), and phosphorylation of ERK1/2 was analyzed by immunoblot. (F) RAW 264.7 cells were transfected with an
AP-1 luciferase reporter plasmid along with expression vectors for TPL-2, BCL-3, or NF-ĸB p50 for 24 h as indicated, and reporter activity was measured. Data
are representative of 3 independent experiments. Data in C, D, and F are shown as the mean ± SEM and were analyzed by 2-way ANOVA (C and D) and 1-way
ANOVA (F). ***P < 0.001; **P < 0.01; *P < 0.03.
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Fig. 3. BCL-3 interacts with TPL-2. (A) HEK293T cells were transfected for 24 h with plasmids encoding FLAG-BCL-3 and TPL-2 prior to immunoprecipitation of
FLAG-BCL-3 and immunoblot using anti–TPL-2 antibody. (B) TPL-2 was immunoprecipitated from THP-1 lysates and immunoblotted using anti–BCL-3 antibody.
Inhibition of coimmunoprecipitation by the immunizing TPL-2 peptide (peptide) demonstrated antibody specificity. (C) Nfkb1−/− MEFs were transfected with
plasmids encoding FLAG-BCL-3 and TPL-2 for 24 h. Cells were pretreated with 20 μM MG132 for 2 h prior to analysis. Immunoprecipitated FLAG-BCL-3 was
immunoblotted with anti–TPL-2 antibody. (D) HEK293T cells were transfected with plasmids encoding FLAG-BCL-3, TPL-2, and a kinase dead mutant of TPL-2
(D270A) for 24 h prior to immunoprecipitation of FLAG-BCL-3 and immunoblot using anti–TPL-2 antibody. (E) TPL-2 in vitro kinase assay in the presence or
absence of recombinant BCL-3, using MEK1 as a substrate. Phosphorylation of MEK1 was detected by anti–p-MEK1 immunoblot. (F) Representative confocal
immunofluorescence micrograph of 3T3 cells transfected with plasmids encoding TPL-2 and BCL-3 (indicated at the left) and immunostained for TPL-2 and
BCL-3 (indicated at the top). DAPI nuclear stain is shown in blue. (Magnification: 40×.) (G) Quantification of TPL-2 subcellular localization. The subcellular
distribution of TPL-2 was scored as nuclear and cytoplasmic (CN) or predominantly cytoplasmic (C) and presented as the percentage of total cells counted.
Data are presented as the mean ± SEM of 3 independent experiments (n ≥ 50 cells analyzed per experiment). (H) Nuclear and cytoplasmic fractions of
HEK293T cells transfected with plasmids encoding TPL-2 and BCL-3 for 24 h were analyzed by immunoblot using the indicated antibodies. All data are
representative of at least 3 independent experiments. Data in G were analyzed by Student’s t test; ****P < 0.0001.
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MAPK pathway and the subsequent transcriptional response to
TLR activation. However, an in vitro kinase assay using recombi-
nant MEK1 as substrate revealed that BCL-3 does not inhibit TPL-
2–mediated phosphorylation of MEK1 (Fig. 3E). Thus, BCL-3 is
not a direct inhibitor of TPL-2 kinase activity.
Since it is thought that TPL-2 is a cytoplasmic protein, while
BCL-3 is localized to the nucleus, we were interested in deter-
mining the subcellular localization of the TPL-2/BCL-3 interac-
tion. This was done using immunofluorescence microscopy and
immunoblot analysis of nuclear and cytoplasmic extracts. As
predicted, when TPL-2 was expressed alone, it was predomi-
nantly found in the cytoplasm (Fig. 3 F–H). Unexpectedly, how-
ever, when coexpressed with BCL-3, TPL-2 showed a striking
redistribution from the cytoplasm to the nucleus where it colo-
calized with BCL-3 (Fig. 3 F–H). Collectively, these data identify
BCL-3 and TPL-2 as interacting partners and reveal that BCL-3
can drive the redistribution of TPL-2 from the cytoplasm to the
nucleus. The data demonstrate that BCL-3 and TPL-2 interaction
occurs in the nucleus; however, the potential for interaction in the
cytoplasm cannot be ruled out.
TPL-2 Is a Nucleocytoplasmic Shuttling Protein. Next, we considered
the mechanisms and consequences of TPL-2 localization to the
nucleus. Subcellular fractionation demonstrated a readily detect-
able pool of TPL-2 protein in the nuclear fraction of untreated
WT BMDMs (Fig. 4A). Both cytoplasmic and nuclear levels of
TPL-2 protein rapidly decreased following stimulation with LPS,
consistent with the rapid proteasomal degradation of active TPL-2.
Of note, after LPS stimulation, TPL-2 protein disappeared more
rapidly from the nuclear fraction than from the cytoplasmic frac-
tion, suggesting that it might be more unstable in the nucleus (Fig.
4 A and B).
To explore the mechanisms underlying the nuclear localization
of TPL-2, we treated cells expressing TPL-2 with leptomycin-B
(LMB), an inhibitor of Crm1/Exportin-1–mediated nuclear ex-
port. This led to a striking accumulation of TPL-2 in the nucleus
and strongly suggests that TPL-2 is a nucleocytoplasmic shuttling
Fig. 4. TPL-2 is a nuclear cytoplasmic shuttling protein. (A) WT BMDMs were stimulated with LPS (10 ng/mL) for the indicated times before equal amounts of
nuclear and cytoplasmic protein were analyzed by immunoblot using the indicated antibodies. (B) Quantification of TPL-2 protein levels in cytoplasmic (C) and
nuclear (N) fractions relative to loading controls for 3 independent experiments. (C) Representative confocal immunofluorescence micrographs of 3T3 cells
transfected for 24 h with plasmids encoding TPL-2 and p105 and either untreated (Unt) or treated with leptomycin B (LMB) (20 nM for 2 h). DAPI nuclear stain
is shown in blue. (Magnification: 40×.) (D) Percentage (%) of cells from (C) displaying cytoplasmic (C) or nuclear and cytoplasmic (CN) distribution of TPL-2. (E)
Representative confocal immunofluorescence micrograph of Nfkb1−/− MEFs cells transfected with plasmid encoding TPL-2 for 24 h. DAPI nuclear stain is
shown in blue. (Magnification: 40×.) (F) Percentage (%) of cells from (E) displaying cytoplasmic (C) or nuclear and cytoplasmic (CN) distribution of TPL-2. (G)
Identification of a conserved NES in the N terminus of TPL-2. (H) The TPL-2 NES sequence is sufficient to mediate the nuclear export of a REV-GFP fusion
protein. DAPI nuclear stain is shown in blue. (Magnification: 40×.) (I) Immunofluorescence microscopy of 3T3 cells transfected for 24 h with plasmid encoding
TPL-2 or a TPL-2 mutant lacking the NES (ΔNES). DAPI nuclear stain is shown in blue. (Magnification: 40×.) (J) Percentage (%) of cells from I displaying cy-
toplasmic (C) or nuclear and cytoplasmic (CN) distribution of TPL-2. All data are representative of at least 3 independent experiments. Data in D, F, and J are
shown as the mean ± SEM of 3 independent experiments (n ≥ 50 cells per experiment) and were analyzed by Student’s t test. Data in B were analyzed by
2-way ANOVA. ns, not significant; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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protein (Fig. 4 C and D). Interestingly, coexpression of p105
prevented LMB-induced nuclear localization of TPL-2 (Fig. 4 C
and D), and in cells lacking p105, TPL-2 constitutively localized
to the nucleus without the requirement for inhibition of Crm1/
Exportin-1 (Fig. 4 E and F). Thus, these data indicate that TPL-2
is a nucleocytoplasmic shuttling protein that can be sequestered
in the cytoplasm by p105. These findings are supported by a
recent proteomic analysis of Crm1-mediated nuclear export which
identified TPL-2 as a Crm1 cargo along with more than 1,000
other proteins (25).
Analysis of the TPL-2 amino acid sequence identified a pu-
tative conserved N-terminal NES that is predicted to mediate
LMB-sensitive Crm1/Exportin-1–mediated nuclear export (26, 27)
(Fig. 4G). Insertion of this putative NES into a NES-deficient
Rev-GFP fusion protein (28) was sufficient to export the Rev-
GFP protein from the nucleus to the cytoplasm, establishing this
sequence of TPL-2 as a bone fide NES (Fig. 4H). Moreover, de-
letion of the NES led to the accumulation of TPL-2 in the nucleus
(Fig. 4 I and J) to levels similar to that induced by LMB treatment
(Fig. 4C) but did not inhibit interaction with p105 or BCL-3 (SI
Appendix, Fig. S3). These data establish TPL-2 as a nucleocyto-
plasmic shuttling protein containing an N-terminal NES.
TPL-2 Undergoes Ubiquitination and Proteasomal Degradation in the
Nucleus. In addition to inducing the nuclear accumulation of
TPL-2, LMB treatment also led to a dramatic reduction in cel-
lular TPL-2 protein levels that could be restored by treatment
with the proteasome inhibitor MG132 (Fig. 5A). These data in-
dicate that TPL-2 may be much more sensitive to proteasomal
degradation when it is in the nucleus. This is supported by the
finding that, similar to LMB treatment, inhibition of the pro-
teasome led to the nuclear accumulation of TPL-2 which could
be reversed by coexpression of p105 (Fig. 5 B and C). Moreover,
deletion of the NES of TPL-2 (TPL-2ΔNES) led to reduced TPL-2
levels in cells that could be restored by proteasome inhibition (Fig.
5D). p105 expression blocked the nuclear accumulation of
TPL-2ΔNES protein (Fig. 5 E and F) and, like proteasome in-
hibition, stabilized both full-length TPL-2 and TPL-2ΔNES protein
levels (Fig. 5G). Hoxb8-immortalized murine myeloid progenitor
cells in which Tpl2 was knocked out using CRISPR/Cas9 (SI Ap-
pendix, Fig. S4) were reconstituted with TPL-2 or TPL-2ΔNES us-
ing retroviral transduction prior to in vitro differentiation to
macrophages (SI Appendix, Fig. S5). Consistent with transient
transfection experiments, TPL-2ΔNES protein levels were re-
duced compared to full-length TPL-2 (SI Appendix, Fig. S5). LPS
stimulation induced the degradation of both full-length TPL-2 and
TPL-2ΔNES protein levels; however, the degradation of TPL-2ΔNES
protein levels occurred more rapidly compared to full-length TPL-2
(Fig. 5 H and I). An in-cell ubiquitination assay revealed that
TPL-2 is highly polyubiquitinated and that this can be inhibited by
p105 (Fig. 5J). Importantly, the vast majority of polyubiquitinated
TPL-2 is detected in the nuclear fraction of cellular extracts (Fig.
5K). Collectively, these data identify the nucleus as the site of
TPL-2 polyubiquitination and proteasomal degradation and reveal
cytoplasmic sequestration of TPL-2 as a key mechanism for the
stabilization of TPL-2 by p105.
BCL-3 Controls TPL-2 Degradation by the Proteasome. In light of
these findings, we predicted that BCL-3–induced nuclear local-
ization of TPL-2 would lead to TPL-2 degradation and provide
an explanation for the ability of BCL-3 to inhibit MAPK activity
(Figs. 1 and 2). Indeed, expression of BCL-3 induced a dramatic
reduction in TPL-2 protein levels that was reversed by protea-
some inhibition (Fig. 6A). Moreover, the half-life of TPL-2 in LPS-
stimulated Bcl3−/− BMDMs was ∼2-fold greater than that of WT
BMDMs (Fig. 6 B and C). In addition, compared to WT cells,
Bcl3−/− BMDMs contained significantly less nuclear, and more
cytoplasmic, TPL-2 in both the presence and the absence of LPS
stimulation (Fig. 6D). As expected from the data above (Fig. 5),
the expression of p105 prevented BCL-3–induced degradation of
TPL-2 (Fig. 6E). There were equivalent levels of p105 expression
in LPS-stimulated Bcl3−/− cells compared to WT cells (Fig. 6F)
consistent with our previous findings (19). Thus, by shifting the
equilibrium of TPL-2 nucleocytoplasmic shuttling toward the nu-
cleus, BCL-3 increases the proteasomal degradation of TPL-2 to
limit MAPK activation.
BCL-3 Sets the Activation Threshold for LPS-Induced Responses. BCL-
3 regulation of the MAPK pathway clearly suppresses the ex-
pression of certain genes induced by 10 ng/mL LPS (Fig. 1) and
will co-operate with its regulation of NF-ĸB activity to dictate the
magnitude and duration of transcriptional responses induced by
medium-to-high quantities of TLR ligand (19). We were also in-
terested in whether BCL-3 regulates the set point of the MAPK
activation threshold. In WT cells this limits MAPK activation at
low TLR ligand concentrations and means that the MAPK path-
way, unlike the NF-κB pathway, is not activated in a linear fashion
(13). Thus, we first measured MAPK activity in WT and Bcl3−/−
BMDMs stimulated with a range of LPS concentrations (1 to
10 ng/mL). Strikingly, the MAPK pathway was activated at signifi-
cantly lower concentrations of LPS in Bcl3−/− BMDMs compared
to WT BMDMs (Fig. 7A). As expected (19, 20), the activation of
the NF-ĸB pathway, as measured by IĸBα degradation, was
equivalent between WT and Bcl3−/− cells (SI Appendix, Fig. S6).
To assess the impact of this altered MAPK activation threshold
in Bcl3−/− macrophages, we next analyzed LPS-induced produc-
tion of cytokines and chemokines. At 10 to 100 ng/mL of LPS, Tnf
mRNA was significantly higher in Bcl3−/− BMDMs due to loss of
BCL-3–mediated regulation of the NF-ĸB pathway. At the low
levels of LPS (1 ng/mL) that induced MAPK activity in Bcl3−/−,
but not WT cells, there were no significant differences in Tnf
mRNA between WT and Bcl3−/− macrophages (Fig. 7B). How-
ever, TLR-induced production of TNFα protein is known to rely
on MAPK-dependent posttranscriptional mechanisms controlled
by TPL-2 activation (4, 6). Thus, we also examined cytokine re-
lease from LPS-treated BMDMs. Strikingly, only Bcl3−/− BMDMs
released TNFα in response to stimulation with the low doses of
LPS that activated the MAPK pathway only in Bcl3−/− BMDMs
(Fig. 7C). Similarly, low-dose LPS stimulation resulted in the
production of the IL-1α, IL-1β, and IL-13 cytokines by Bcl3−/−, but
not WT, BMDMs (Fig. 7C). This effect was selectively associated
with proinflammatory cytokines because the production of the
CXCL1, CCL2, CCL3, and CCL4 chemokines, which relies pri-
marily on the NF-ĸB pathway (7), was equivalent betweenWT and
Bcl3−/− cells treated with the same low concentrations of LPS (Fig.
7C). Thus, BCL-3 controls the MAPK activation threshold to
prevent the production of proinflammatory cytokines when cells
are exposed to very low levels of LPS.
As expected (19), the serum of Bcl3−/− mice injected with LPS
(2.5 μg) contained more cytokines and chemokines than similarly
treated WT animals (SI Appendix, Fig. S7). However, in un-
challenged mice, serum concentrations of TNFα, IL-13, IL-1α,
and IL-β were all found to be significantly higher in Bcl3−/− mice
than in WT counterparts, while the concentrations of the che-
mokines CXCL1, CCL2, and CCL4 and GM-CSF were not dif-
ferent (Fig. 7D). These data mirror those seen with BMDMs to
suggest that BCL-3, by regulating the MAPK activation thresh-
old, sets the baseline level of proinflammatory cytokine pro-
duction in vivo.
Discussion
This study identifies a role for the IĸB protein BCL-3 in limiting
inflammatory responses to TLR activation independently of its
previously described role in regulating NF-ĸB transcriptional
activity (19). It establishes BCL-3 as a unique factor that integrates
the control of the NF-ĸB and MAPK pathways in the nucleus and,
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Fig. 5. TPL-2 is degraded in the nucleus. (A) HEK293T cells transfected for 24 h with plasmid encoding TPL-2 were treated with LMB (20 nM for 6 h) and/or
MG132 (20 μM) and analyzed by immunoblot using the indicated antibodies. (B) Representative confocal immunofluorescence micrograph of 3T3 cells
transfected for 24 h with plasmids encoding TPL-2 and p105 and treated with MG132 (20 μM for 2 h). DAPI nuclear stain is shown in blue. (Magnification: 40×.)
(C) Percentage (%) of cells from B displaying cytoplasmic or nuclear and cytoplasmic distribution of TPL-2. The subcellular distribution of TPL-2 was scored as
nuclear and cytoplasmic (CN) or predominantly cytoplasmic (C) and presented as the percentage of total cells counted. Data are presented as the mean ± SEM
of 3 independent experiments (n ≥ 50 cells per experiment). (D) HEK293T cells were transfected for 24 h with plasmids encoding TPL-2 or TPL-2ΔNES and
treated with MG132 (20 μM, 4 h) before analysis by immunoblot using the indicated antibodies. (E) Representative confocal immunofluorescence micrograph
of 3T3 cells transfected with plasmids encoding TPL-2ΔNES and p105 for 24 h. DAPI nuclear stain is shown in blue. (Magnification: 40×.) (F) Percentage (%) of
cells from E displaying cytoplasmic (C) or nuclear and cytoplasmic (CN) distribution of TPL-2ΔNES. Data are presented as the mean ± SEM of 3 independent
experiments (n ≥ 50 cells per experiment). (G) HEK293T cells transfected with plasmids encoding TPL-2, TPL-2ΔNES, and XP-p105 for 24 h and analyzed by
immunoblot using the indicated antibodies. (H) Tpl2−/− Hoxb8-immortalized murine progenitor cells were retrovirally transduced with TPL-2 or TPL-2ΔNES
prior to differentiation into macrophages, stimulation with LPS (10 ng/mL) for the indicated times, and immunoblotting with the indicated antibodies. (I) TPL-2
protein levels relative to loading controls and normalized to the appropriate untreated control (0 min). (J) HEK293T cells were transfected with plasmids
encoding Myc-TPL-2, FLAG-p105, and HA-tagged ubiquitin for 24 h. Lysates were immunoprecipitated with antibody against TPL-2 and immunoblotted with
antibody against HA. (K) HEK293T cells were transfected with plasmids encoding Myc-TPL-2 and HA-tagged ubiquitin for 24 h. Nuclear (N) and cytoplasmic (C)
fractions were immunoprecipitated with anti–TPL-2 antibody and immunoblotted with antibody against HA. All data are representative of at least 3 in-
dependent experiments. Data in C and F were analyzed by Student’s t test. Data in I were analyzed by 2-way ANOVA. **P < 0.01; ****P < 0.0001.
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furthermore, identifies the nucleus as a key site for the regulation
of TLR-induced MAPK activity.
The proteasomal degradation of TPL-2 has long been recog-
nized as a key factor in limiting TLR- and cytokine-induced MAPK
activity (16). However, apart from the stabilization of TPL-2 by
p105 (14, 16), relatively little is known about the mechanisms
controlling this process. The compartmentalization of TPL-2
ubiquitination and proteasomal degradation to the nucleus indi-
cates that factors that influence TPL-2 subcellular localization will
have a profound impact on MAPK activity. Thus, the opposing
effects of BCL-3 and p105 on TPL-2 nuclear localization are
mirrored by significant changes in TPL-2 stability and TLR-
induced MAPK activity. The mechanisms underlying TPL-2 nuclear
localization are presently unclear. Although sequence analysis
of TPL-2 does not reveal an obvious nuclear localization se-
quence, this does not rule out that TPL-2 may possess intrinsic
nuclear localization properties. The presence of TPL-2 in the
nucleus of Bcl3−/− cells suggests that BCL-3 is not required for
the nuclear import of TPL-2; however, it is possible that another
factor(s) may play a role in TPL-2 nuclear import. It is interesting
to note that the interaction of TPL-2 with 14–3-3 has previously
been reported to promote TPL-2–mediated activation of the
MAPK pathway (29). Previous studies have shown that 14–3-
3 also acts as a molecular chaperone to sequester a number of
proteins in the cytoplasm, including IĸBα:p65 complexes (30),
HDACs (31), and CDC25 (32). It remains to be seen if the se-
questration of TPL-2 in the cytoplasm contributes to 14–3-3–
mediated activation of the MAPK pathway. The dependence of
TPL-2 activation on proteasomal degradation of p105 excludes the
use of proteasome inhibitors for the investigation of TPL-2
degradation in the nucleus. The identification of the E3 ligase
complex responsible for TPL-2 ubiquitination will be important
Fig. 6. BCL-3 promotes the degradation of TPL-2. (A) HEK293T cells were transfected with plasmids encoding Myc-BCL-3 and FLAG-TPL-2 for 16 h and treated
with MG132 (20 μM for 4 h) as indicated. Relative protein levels were determined by immunoblotting using the indicated antibodies. (B) WT and Bcl3−/−
BMDMs were stimulated with LPS (10 ng/mL) for the indicated times prior to analysis by immunoblotting using the indicated antibodies. (C) TPL-2 levels were
quantified relative to loading controls for 3 independent experiments as shown in B. (D) WT and Bcl3−/− BMDMs were untreated (Unt) or stimulated with LPS
(10 ng/mL for 10 min) before nuclear and cytoplasmic fractions were analyzed by immunoblotting using anti–TPL-2 antibody. (E) HEK293T cells were
transfected for 16 h with plasmids encoding TPL-2, XP-p105, and Myc-BCL-3 as indicated. Relative protein levels were determined by immunoblotting. (F) WT
and Bcl3−/− BMDMs were stimulated with LPS (10 ng/mL) for the indicated times prior to analysis by immunoblotting using the indicated antibodies. All data
are representative of at least 3 independent experiments. P < 0.0005.
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to further define the mechanism controlling TPL-2 degradation
and will likely reveal additional checkpoints controlling TLR re-
sponses that could be targeted for the therapeutic modulation of
inflammatory responses.
The essential requirement of MAPK activation for the initia-
tion of inflammation is perhaps most clearly demonstrated in
studies of transgenic mice with constitutive activation of NF-ĸB
in intestinal epithelial cells (7). These cells show elevated ex-
pression of NF-ĸB target genes including cytokines, such as Tnf,
and chemokines, such as Ccl2, but in the absence of MAPK
activation the production of TNFα protein was too low to induce
inflammation. Strikingly, the mechanisms of MAPK-dependent
posttranscriptional control did not apply to the production of
chemokines which were abundantly expressed in response to
NF-ĸB activation alone. The result was leukocyte infiltration of
the lamina propria in the absence of inflammatory tissue
damage (7). Thus, the absence of MAPK activation uncoupled
the activation of NF-ĸB from inflammation. Likewise, the
MAPK activation threshold will determine the precise set point
of when a cell responds to TLR activation irrespective of the
NF-ĸB pathway. The lower MAPK activation threshold in Bcl3−/−
cells reveals that the TPL-2 half-life is a critical determinant in
setting the TLR ligand concentrations required to initiate in-
flammation. The selective dependence of proinflammatory cy-
tokine, but not chemokine, production on MAPK activation is
reflected in the patterns of cytokine and chemokine expression at
subthreshold levels of the TLR ligand in the absence of BCL-3 in
vitro and in vivo.
This study establishes BCL-3 as a unique factor that regulates
the MAPK activation by modifying the stability of an active apical
kinase. It suggests that the modulation of BCL-3 expression by
cytokines such as IL-10 (33) may also shift the MAPK threshold
and thereby raise the concentration of ligand required to initiate
inflammation through TLRs. It also identifies BCL-3 as a target
for modulating inflammatory responses by altering the sensitivity
of innate cells to TLR stimulation. Modulating the stability or
nuclear export of TPL-2 would have a similar effect; for example,
reduced TPL-2 nuclear export would increase the MAPK activa-
tion threshold and the concentration of TLR ligand or cytokine
required to initiate an inflammatory response. The potential to
modulate the MAPK activation threshold is an attractive strategy
for limiting inflammatory responses without preventing the ca-
pacity of cells to initiate inflammation when a clear threat is en-
countered. It is important to further understand mechanisms
controlling the MAPK activation threshold so that this potential
therapeutic approach can be successfully exploited.
The dual function of BCL-3 as an inhibitor of both NF-ĸB
transcriptional activity and MAPK activity establish it as a key
factor integrating control of TLR responses in the nucleus. The
involvement of the ubiquitin proteasome system in BCL-3–
mediated control of both pathways further underlines the impor-
tance of this cellular mechanism in the control of inflammatory
responses. However, the importance of TPL-2 nuclear localization
in the control of MAPK responses was unexpected and challenges
the accepted models of signal transduction that lead from receptor
proximal events in the cytoplasm, through incremental stages, to
the activation of transcription factors in the nucleus. Instead, this
Fig. 7. BCL-3 regulates the MAPK response threshold to TLR activation. (A) WT and Bcl3−/− BMDMs were stimulated with the indicated concentration of LPS,
and phospho-ERK1/2 levels were measured by immunoblotting at the indicated time points. Data are representative of 3 independent experiments. (B) WT
and Bcl3−/− BMDMs were stimulated with the indicated concentrations of LPS, and Tnf mRNA levels were measured by qPCR. Data are presented as the
mean ± SEM and are representative of 3 independent experiments. (C) WT and Bcl3−/− BMDMs were stimulated with the indicated concentrations of LPS, and
levels of secreted cytokines and chemokines were measured. The means ± SEM of 3 independent experiments are shown. (D) Serum fromWT and Bcl3−/−mice
was analyzed for the indicated factors. The means ± SEM are presented. Data were analyzed by 2-way ANOVA with Sidak multiple comparisons test (B and C)
or Student’s t test (D). ns, not significant; *P < 0.05; ***P < 0.001.
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study indicates that the dynamic movement of key upstream ac-
tivators of signaling pathways between the cytoplasm and the
nucleus can play a critical role in determining the outcome of
receptor activation. The potential involvement of similar mech-
anisms in the control of other immunoreceptor-mediated responses
requires investigation.
In summary, this study identifies the nuclear cytoplasmic shut-
tling of TPL-2 as a mechanism regulating TLR-induced MAPK
activity and the MAPK activation threshold. Our data establish
BCL-3 as a unique factor that integrates the regulation of MAPK
activation and NF-ĸB activity in the nucleus. The possibility of
modifying MAPK activity, and the MAPK activation threshold,
through altering TPL-2 localization, stability, or interaction with
BCL-3 offers the potential to modify inflammatory responses for
therapeutic benefit.
Materials and Methods
Cell Culture, CRISPR/Cas9 Gene Editing, and Retroviral Transduction. HEK293T
and RAW264.7 cells were cultured in Dulbecco’s Modified Eagle Media
(DMEM) containing 10% fetal bovine serum (FBS), and 3T3s MEFs in DMEM
containing bovine calf serum with 2 mM glutamine and 100 units/mL peni-
cillin/streptomycin. THP-1 cells were cultured in RPMI containing 10% FBS
with of 2 mM glutamine and 100 units/mL penicillin/streptomycin. BMDMs
were prepared in vitro as described previously (34). Hoxb8-immortalized
murine myeloid progenitor cells and derived macrophages were generated
as previously described and cultured in RPMI supplemented with 10% FBS,
GM-CSF (20 ng/mL), and β-estradiol (1 μM) (35). CRISPR/Cas9 gene editing
and retroviral transduction are detailed in SI Appendix, Materials and
Methods.
Plasmids, Transfection, and Reagents. Mammalian expression vectors for
BCL-3 and p105 were as previously described (19). TPL-2-MYC and TPL-
2D270A- MYC in pcDNA3 were generous gifts from Stephen Ley, Francis
Crick Institute, London (14). pcDNA3.1-TPL-2-N-FLAG expression vectors
were generated by Genscript using TPL-2 cDNA accession number
NM_053847. pRevGFP and pRev(1.4)-GFP were generous gifts from Beric
Henderson, University of Sydney, Australia, and are described elsewhere
(28). Transfection reagents and the cloning of the TPL-2 NES into pREV(1.4)-
GFP are detailed in SI Appendix, Materials and Methods.
Western Blot and Immunoprecipitation.Whole-cell or cytoplasmic and nuclear
proteins were extracted as previously described (36) and as detailed in SI
Appendix, Materials and Methods.
Luciferase Assay. The AP-1 promoter reporter plasmid (Clontech) and the
Renilla-luciferase expression vector pRL-TK (Promega) were used as detailed
in SI Appendix, Materials and Methods.
Gene Expression. Targeted RNA-seq analysis was performed using the QIA-seq
Mouse Inflammation and Immunity Transcriptome-targeted RNA Panel (RMM-
005Z) as detailed in SI Appendix, Materials and Methods.
Cytokine Analysis. Cytokine concentrations for supernatants and serum
samples weremeasured using BioRad Bio-plex Promouse cytokine Grp1 Panel
23-plex according to the manufacturer’s instructions using the Bio-Plex
200 system as detailed in SI Appendix, Materials and Methods.
Immunofluorescence Microscopy. Cells were fixed and permeabilized with ice-
cold methanol for 15 min, blocked in phosphate-buffered saline/0.05%
Tween containing 5% bovine serum albumin, and incubated with antibodies
as detailed in SI Appendix, Materials and Methods.
Kinase Assay. TPL-2 kinase assays were performed using GST-MEK1 as a
substrate as described in SI Appendix, Materials and Methods.
Animal Studies. Bcl3−/− mice (37) were bred in‐house (C57BL/6 background);
WT C57BL6/J mice were from Charles River Research Models and Services.
Animal work was carried out with ethical approval from the University of
Glasgow under the revised Animal (Scientific Procedures) Act of 1986 and
the European Union Directive 2010/63/EU.
Data Availability. All data and associated protocols are available in SI Ap-
pendix. Plasmids and cell lines are available on request.
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